NGM Biopharmaceuticals (NGM) Prices 4.63M Share Common Offering at $27/Sh

NGM Biopharmaceuticals Inc. (NASDAQ: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced the pricing of an underwritten public offering of 4,629,630 shares of its common stock at a price to the public of $27.00 per share. The aggregate gross proceeds from the offering are expected to be approximately $125.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by NGM. The offering is expected to close on or about January 8, 2021, subject to customary closing conditions. In connection with the offering, NGM has granted the underwriters a 30-day option to purchase up to an additional 694,444 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Goldman Sachs & Co. LLC, Citigroup and Cowen are acting as joint book-running managers for the offering. Raymond James and B. Riley Securities are acting as lead managers for the offering.

The shares described above are being offered by NGM pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by NGM with the Securities and Exchange Commission (the “SEC”) and was declared effective on June 16, 2020.

You May Also Be Interested In

• Aveanna Healthcare prices secondary offering at $11.75 per share
• Werewolf Therapeutics to merge with Ambros in $150M private placement
• MicroCloud Hologram acquires 140,268 MicroStrategy shares via structured note